Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency

According to the WHO, cancer is the second leading cause of death in the world. This is an important global problem and a major challenge for researchers who have been trying to find an effective anticancer therapy. A large number of newly discovered compounds do not exert selective cytotoxic activity against tumorigenic cells and have too many side effects. Therefore, research on muramyl dipeptide (MDP) analogs has attracted interest due to the urgency for finding more efficient and safe treatments for oncological patients. MDP is a ligand of the cytosolic nucleotide-binding oligomerization domain 2 receptor (NOD2). This molecule is basic structural unit that is responsible for the immune activity of peptidoglycans and exhibits many features that are important for modern medicine. NOD2 is a component of the innate immune system and represents a promising target for enhancing the innate immune response as well as the immune response against cancer cells. For this reason, MDP and its analogs have been widely used for many years not only in the treatment of immunodeficiency diseases but also as adjuvants to support improved vaccine delivery, including for cancer treatment. Unfortunately, in most cases, both the MDP molecule and its synthesized analogs prove to be too pyrogenic and cause serious side effects during their use, which consequently exclude them from direct clinical application. Therefore, intensive research is underway to find analogs of the MDP molecule that will have better biocompatibility and greater effectiveness as anticancer agents and for adjuvant therapy. In this paper, we review the MDP analogs discovered in the last 10 years that show promise for antitumor therapy. The first part of the paper compiles the achievements in the field of anticancer vaccine adjuvant research, which is followed by a description of MDP analogs that exhibit promising anticancer and antiproliferative activity and their structural changes compared to the original MDP molecule.

[1]  Vesna Petrović Peroković,et al.  Design, Synthesis, and Biological Evaluation of Desmuramyl Dipeptides Modified by Adamantyl-1,2,3-triazole , 2021, Molecules.

[2]  J. Plavec,et al.  Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their In Vivo Adjuvant Activity , 2021, Journal of medicinal chemistry.

[3]  R. M. Khaitov,et al.  Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine , 2021, Frontiers in Immunology.

[4]  M. Barone,et al.  Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body , 2021, Frontiers in Immunology.

[5]  M. Pucciarelli,et al.  A Novel Salmonella Periplasmic Protein Controlling Cell Wall Homeostasis and Virulence , 2021, Frontiers in Microbiology.

[6]  Shatha S. M. Al-azzawi.  Abstract , 2020, Allergy.

[7]  N. Moskaleva,et al.  Determination of the immunostimulatory drug - Glucosoaminyl-Muramyl-Dipeptide - in human plasma using high performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study. , 2020, Biomedical chromatography : BMC.

[8]  H. Ibrahim,et al.  Anti-neoplastic and immunomodulatory potency of co-treatment based on bovine lactoferrin and/or muramyl dipeptide in tumor-bearing mice. , 2020, Toxicology research.

[9]  N. Taçyıldız,et al.  Muramyl Tripeptide Plus Chemotherapy Reduces Metastasis in Non-Metastatic Osteosarcoma: A Single-Center Experience , 2020, Asian Pacific journal of cancer prevention : APJCP.

[10]  J. Byrd,et al.  Activation of the Intracellular Pattern Recognition Receptor NOD2 Promotes Acute Myeloid Leukemia (AML) Cell Apoptosis and Provides a Survival Advantage in an Animal Model of AML , 2020, The Journal of Immunology.

[11]  H. Hang,et al.  Translation of peptidoglycan metabolites into immunotherapeutics , 2019, Clinical & translational immunology.

[12]  S. Moosa,et al.  Identifying the Neurogenetic Framework of Crohn's Disease Through Investigative Analysis of the Nucleotide-binding Oligomerization Domain-containing Protein 2 Gene Mutation , 2019, Cureus.

[13]  L. Milković,et al.  Design, synthesis and biological evaluation of immunostimulating mannosylated desmuramyl peptides , 2019, Beilstein Journal of Organic Chemistry.

[14]  B. Ramaswamy,et al.  Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors , 2019, Clinical Cancer Research.

[15]  D. Philpott,et al.  NOD1 and NOD2 in inflammation, immunity and disease. , 2019, Archives of biochemistry and biophysics.

[16]  Wei Gao,et al.  Muramyl Dipeptide Induces Reactive Oxygen Species Generation Through the NOD2/COX-2/NOX4 Signaling Pathway in Human Umbilical Vein Endothelial Cells , 2018, Journal of cardiovascular pharmacology.

[17]  H. Kitaura,et al.  Role of Muramyl Dipeptide in Lipopolysaccharide-Mediated Biological Activity and Osteoclast Activity , 2018, Analytical cellular pathology.

[18]  X. Wen,et al.  Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis. , 2018, Journal of medicinal chemistry.

[19]  S. Granjeaud,et al.  Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia , 2017, Front. Immunol..

[20]  C. Dong,et al.  Immune Cell-Mediated Biodegradable Theranostic Nanoparticles for Melanoma Targeting and Drug Delivery. , 2017, Small.

[21]  Suhua Wang,et al.  Antagonizing NOD2 Signaling with Conjugates of Paclitaxel and Muramyl Dipeptide Derivatives Sensitizes Paclitaxel Therapy and Significantly Prevents Tumor Metastasis. , 2017, Journal of medicinal chemistry.

[22]  A. Gudkov,et al.  Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses , 2016, PloS one.

[23]  D. Heymann,et al.  L-MTP-PE and zoledronic acid combination in osteosarcoma: preclinical evidence of positive therapeutic combination for clinical transfer. , 2016, American journal of cancer research.

[24]  Marianna Aprile,et al.  Stimulation of Innate and Adaptive Immunity by Using Filamentous Bacteriophage fd Targeted to DEC-205 , 2015, Journal of immunology research.

[25]  R. Nahta,et al.  Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC) , 2015, Vaccines.

[26]  E. Lee,et al.  Lifetime effectiveness of mifamurtide addition to chemotherapy in nonmetastatic and metastatic osteosarcoma: a Markov process model analysis , 2015, Tumor Biology.

[27]  Andrew D. Miller,et al.  Molecular Adjuvants Based on Nonpyrogenic Lipophilic Derivatives of norAbuMDP/GMDP Formulated in Nanoliposomes: Stimulation of Innate and Adaptive Immunity , 2015, Pharmaceutical Research.

[28]  P. Trzonkowski,et al.  Synthesis and antiproliferative activity of conjugates of adenosine with muramyl dipeptide and nor-muramyl dipeptide derivatives. , 2014, Bioorganic & medicinal chemistry letters.

[29]  G. Eberl,et al.  The biology of bacterial peptidoglycans and their impact on host immunity and physiology , 2014, Cellular microbiology.

[30]  E. Lee,et al.  The addition of mifamurtide to chemotherapy improves lifetime effectiveness in children with osteosarcoma: a Markov model analysis , 2014, Tumor Biology.

[31]  I. Lewis,et al.  Osteosarcoma treatment - where do we stand? A state of the art review. , 2014, Cancer treatment reviews.

[32]  M. Schilham,et al.  Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ , 2014, Journal of experimental & clinical cancer research : CR.

[33]  C. Rodriguez.  Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks? , 2014, Advances in experimental medicine and biology.

[34]  Ž. Jakopin.  Murabutide revisited: a review of its pleiotropic biological effects. , 2013, Current medicinal chemistry.

[35]  Feng You,et al.  The elimination of MTC-220, a novel anti-tumor agent of conjugate of paclitaxel and muramyl dipeptide analogue, in rats , 2013, Cancer Chemotherapy and Pharmacology.

[36]  P. Trzonkowski,et al.  New conjugates of tuftsin and muramyl dipeptide as stimulators of human monocyte-derived dendritic cells. , 2012, Protein and peptide letters.

[37]  G. Rogler,et al.  Muramyl dipeptide responsive pathways in Crohn’s disease: from NOD2 and beyond , 2013, Cellular and Molecular Life Sciences.

[38]  S. Girardin,et al.  Synthesis and Biological Evaluation of Biotinyl Hydrazone Derivatives of Muramyl Peptides , 2012, Chemical biology & drug design.

[39]  Yuen-Joyce Liu,et al.  Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. , 2011, Current bioactive compounds.

[40]  Xiao-Ling Li,et al.  Muramyl Dipeptide modulates differentiation, maturity of dendritic cells and anti-tumor effect of DC-mediated T cell in acute leukemia children , 2011, Human vaccines.

[41]  P. Trzonkowski,et al.  Recent developments in the synthesis and biological activity of muramylpeptides. , 2011, Current medicinal chemistry.

[42]  Nan Zhao,et al.  Conjugate (MTC-220) of muramyl dipeptide analogue and paclitaxel prevents both tumor growth and metastasis in mice. , 2011, Journal of medicinal chemistry.

[43]  D. Heymann,et al.  Mifamurtide for the treatment of nonmetastatic osteosarcoma , 2011, Expert opinion on pharmacotherapy.

[44]  R. Coffman,et al.  Vaccine adjuvants: putting innate immunity to work. , 2010, Immunity.

[45]  B. Halassy,et al.  Comparative study of structurally related peptidoglycan monomer and muramyl dipeptide on humoral IgG immune response to ovalbumin in mouse. , 2010, International immunopharmacology.

[46]  Wan-Wan Lin,et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis , 2009, Nature.

[47]  G. Scambia,et al.  New taxanes in development , 2008, Expert opinion on investigational drugs.

[48]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Koichi S. Kobayashi,et al.  NLR proteins: integral members of innate immunity and mediators of inflammatory diseases , 2008, Journal of leukocyte biology.

[50]  J. Hampe,et al.  Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients , 2007, Intensive Care Medicine.

[51]  F. Balkwill.  TNF-α in promotion and progression of cancer , 2006, Cancer and Metastasis Reviews.

[52]  J. Auwerx,et al.  The human leukemia cell line, THP-1: A multifacetted model for the study of monocyte-macrophage differentiation , 1991, Experientia.

[53]  G. Rogler,et al.  Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. , 2004, Blood.

[54]  P. Murray,et al.  Role of Nod2 in the Response of Macrophages to Toll-Like Receptor Agonists , 2003, Molecular and Cellular Biology.

[55]  Charles A. Janeway,et al.  IRAK-M Is a Negative Regulator of Toll-like Receptor Signaling , 2002, Cell.

[56]  C. Janeway,et al.  RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems , 2002, Nature.

[57]  G. Núñez,et al.  The NOD: a signaling module that regulates apoptosis and host defense against pathogens , 2001, Oncogene.

[58]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[59]  J. Heijenoort.  Formation of the glycan chains in the synthesis of bacterial peptidoglycan , 2001 .

[60]  G. Bahr,et al.  The Synthetic Immunomodulator Murabutide Controls Human Immunodeficiency Virus Type 1 Replication at Multiple Levels in Macrophages and Dendritic Cells , 2000, Journal of Virology.

[61]  E. Kleinerman,et al.  ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity , 1999, Cancer Immunology, Immunotherapy.

[62]  I. Azuma,et al.  Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model. , 1996, Vaccine.

[63]  H. Tomoda,et al.  Restorative effect of romurtide for thrombocytopenia associated with intensive anticancer drug treatment and/or irradiation in patients with gastrointestinal cancer. , 1995, Anticancer research.

[64]  E. Kleinerman,et al.  Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma , 1995, American journal of clinical oncology.

[65]  I. Azuma,et al.  Review: inducer of cytokines in vivo: overview of field and romurtide experience. , 1992, International journal of immunopharmacology.

[66]  C. Dinney,et al.  Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. , 1992, Cancer research.

[67]  I. Azuma.  Development of the cytokine inducer romurtide: experimental studies and clinical application. , 1992, Trends in pharmacological sciences.

[68]  A. Doyle,et al.  Phase I Trial of ImmTher, a New Liposome‐Incorporated Lipophilic Disaccharide Tripeptide , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[69]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[70]  E. Lederer,et al.  Muramyl peptides. Variation of somnogenic activity with structure , 1984, The Journal of experimental medicine.

[71]  I. Azuma,et al.  Stimulation of nonspecific resistance to infection induced by muramyl dipeptide analogs substituted in the gamma-carboxyl group and evaluation of N alpha-muramyl dipeptide-N epsilon-stearoyllysine , 1983, Infection and immunity.

[72]  E. Lederer,et al.  Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. , 1979, International journal of immunopharmacology.

[73]  C. Dinarello,et al.  The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. , 1978, The Journal of infectious diseases.

[74]  E. Lederer,et al.  Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[75]  E. Lederer,et al.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. , 1974, Biochemical and biophysical research communications.

[76]  A. McPhail,et al.  Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. , 1971, Journal of the American Chemical Society.